Le Lézard
Classified in: Health, Covid-19 virus
Subject: SVY

Hospitals Look for Legal Protections Before Resuming Elective Surgeries Amid COVID-19


DUBLIN, June 4, 2020 /PRNewswire/ -- ResearchAndMarkets.com published a new article on the healthcare industry, "COVID-19: Hospitals Look for Legal Protections Before Restarting Elective Surgeries"

Research and Markets Logo

Hospital revenue has decreased due to a need to focus resources on the coronavirus pandemic. Hospitals have reduced the number of services offered, cancelled or postponed elective surgeries and seen lower patient numbers due to concerns about virus transmission. In addition, hospitals who are in a position to offer elective procedures may delay the restart  without assurances that they will be protected from lawsuits by patients and employees who may have been infected by the coronavirus during the procedure. 

The American Hospital Association has called for protections for its members and some senators have argued that legal protections for employers are essential in order to reopen the economy. However, opponents argue that hospitals should be accountable for their decisions and that sweeping immunity will make it difficult for patients receive compensation in cases where there was demonstrable harm.

To see the full article and a list of related reports on the market, visit "COVID-19: Hospitals Look for Legal Protections Before Restarting Elective Surgeries"

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 07:35
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
Cybin Inc. (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced...

at 07:30
Southern California Clinic Signs Multi-Year Deal for MedMatrix AI Platform
MedBright AI Investments Inc. (the "Company" or "MedBright") today announced that Dermatology Institute & Skin Care Center (DISCC) has signed a 3 year contract to use the MedMatrix AI Platform, including all 5 product modules in their single clinic...

at 07:30
UniDoc Expands AI eHealth Services to Alaska
UniDoc Health Corp. (FRA: L7T) ("UniDoc," or the "Company"), an innovator in the eHealth sector, proudly announces the deployment of an H3 Health Cube to Ketchikan, Alaska. This initiative, in collaboration with Planet Defense, LLC, marks a...

at 07:30
Virax Biolabs to Participate at ESCMID Global 2024
Virax Biolabs Group Limited ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it will be hosting a booth at the European Society of...

at 07:25
Cardiawave appoints Olivier Pierron as its Chief Executive Officer
Cardiawave SA, a French Medtech company that has developed an innovative Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, is delighted to announce the appointment of Olivier Pierron as...

at 07:15
St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Inc., ("Arch" or the "Company") , announced today that a research team from St. Michael's Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac...

More news about Health...


News published on and distributed by: